14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.
Merck Research Laboratories
Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
Bioprojet-Biotech
Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes.
TBA
Fused bicycles as arylketone bioisosteres leading to potent, orally active thiadiazole H3 antagonists.
Merck Research Laboratories
Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.
Griffin Discoveries
Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.
Bioprojet-Biotech
Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists.
Schering-Plough Research Institute
Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Tsukuba Research Institute
Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.
Tsukuba Research Institute
Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
Tsukuba Research Institute
Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands.
The Schering Plough Research Institute
4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H
Vrije Universiteit Amsterdam